Thu.Jul 18, 2024

article thumbnail

Boehringer cuts price of Humira biosimilar in bid to build use

Bio Pharma Dive

The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.

161
161
article thumbnail

Johnson & Johnson’s Q2 2024 net earnings drop 12.8% to $4.6bn

Pharmaceutical Technology

Johnson & Johnson has reported a 12.8% decrease in net earnings for Q2 2024, with figures falling to $4.6bn from $5.3bn in Q2 2023.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

July 18, 2024: Latest Podcast Features Pearl O’Rourke and Stephanie Morain on Waiver of Consent

Rethinking Clinical Trials

In a new episode of our Rethinking Clinical Trials podcast, Drs. Pearl O’Rourke and Stephanie Morain speak with host Dr. Adrian Hernandez about waiver or alteration of informed consent for minimal risk clinical investigations. O’Rourke presented on the topic during the February 10 session of RCT Grand Rounds. Listen and subscribe to the podcast on SoundCloud or Apple Podcasts , and view the full February 10 Grand Rounds webinar.

article thumbnail

Novartis reports 43% increase in net income in Q2 2024

Pharmaceutical Technology

Novartis has reported a 43% increase in net income from continuing operations reaching $3.24bn in the second quarter (Q2) of 2024.

130
130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Argenx posts J&J-rivaling Sjögren's data, massively upscales Vyvgart patient population at R&D day

Fierce Pharma

Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade. | Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade.

81
article thumbnail

Ardelyx sues CMS over revamped kidney disease drug payment bundle

Pharmaceutical Technology

Ardelyx and two other organisations have filed a lawsuit, opposing the HHS' and CMS’ revamped kidney disease payment scheme.

130
130

More Trending

article thumbnail

Bayer eyes Nubeqa’s label expansion in prostate cancer following Phase III win

Pharmaceutical Technology

The Phase III trial evaluating Nubeqa in patients with metastatic hormone-sensitive prostate cancer met its primary endpoint.

130
130
article thumbnail

J&J IRA pricing offer is in, as it sticks with 2025 guidance

pharmaphorum

J&J has three of its top-selling drugs in Medicare pricing negotiations but does not expect a major hit to its finances next year

Drugs 99
article thumbnail

FDA launches new rare disease innovation hub

Pharmaceutical Technology

The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.

130
130
article thumbnail

CordenPharma invests €900M in expanding peptide platform to meet GLP-1 drug demand

BioPharma Reporter

CordenPharma, a US-based contract development and manufacturing organization (CDMO), will be making a â900 million investment over the next three years into expanding its peptide technology platform at its US and Europe sites.

72
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

MHRA approves Pierre Fabre’s vibegron to treat OAB

Pharmaceutical Technology

The UK MHRA has approved Pierre Fabre’s vibegron for the treatment of overactive bladder (OAB) syndrome in adult patients.

130
130
article thumbnail

PBMs will face House committee grilling next week

pharmaphorum

The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare costs in the US.The hearing – scheduled for 23rd July – is part of an ongoing investigation by the committee into PBMs' alleged anticompetitive practices launched last year and spearheaded by chairman James Comer (R-Ky).

article thumbnail

CytoReason secures $80m investment for AI expansion

Pharmaceutical Technology

CytoReason has secured $80m in funding from a consortium of investors to expand and enhance its AI disease models.

130
130
article thumbnail

Nipro's $397.8M investment brings 232 new jobs to Greenville, NC with exciting new facility

Outsourcing Pharma

Japanese medical devices company, Nipro Medical Corporation, a giant in the healthcare and medical device industry, has announced a major investment of $397.8 million to establish its first North American manufacturing center of excellence in Greenville, North Carolina.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Inside Canary Wharf’s infectious disease testing facility

Pharmaceutical Technology

hVIVO specialises in human challenge trials for influenza and RSV therapeutic candidates.

Trials 130
article thumbnail

Study reveals new AI tool predicts recurrence of prostate cancer by a decade

Pharma Times

The most commonly diagnosed cancer in men in the UK leads to over 12,000 annual deaths

article thumbnail

Top 5 CDMOs driving advanced therapies to market amid rising demand and challenges

BioPharma Reporter

Contract development and manufacturing organizations (CDMOs) perform vital services for the biopharmaceutical industry â a role that is growing as cell and gene therapies gain momentum. Here are five of the top CDMOs bringing advanced therapies toward the market.

59
article thumbnail

Amid rocky launch, Boehringer Ingelheim links up with GoodRx to offer its Humira biosimilar at a steep discount

Fierce Pharma

In the year since the Humira biosimilar floodgates opened, AbbVie’s star immunology player has proven tough to drown out. | Through GoodRx, the German drugmaker's Humira copycat is priced 92% cheaper than AbbVie's branded Humira, which still holds 82% of the market despite the biosimilar competition.

56
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Boehringer backs Brainomix AI software for lung fibrosis

pharmaphorum

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases

61
article thumbnail

Roche shows durability of eye disease treatments Vabysmo, Susvimo

Fierce Pharma

After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo | After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo.

56
article thumbnail

Clinical development rates are falling - but it’s not all bad news

pharmaphorum

While clinical development rates are falling, there is still hope in the Phase I bio sector. Learn more about the potential opportunities and positives in this challenging trend.

article thumbnail

Novartis CEO sees IRA impact ‘manageable’ in short run, maintains midterm growth goal

Fierce Pharma

As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.

52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Discover how Marwan Fathallah is transforming DIA and hoping to revolutionize global healthcare

Outsourcing Pharma

At the DIA 60th annual conference in San Diego, senior editor Liza Laws from Outsourcing Pharma had the opportunity to sit down with Marwan Fathallah, President and CEO of DIA.

52
article thumbnail

2nd Covalent Drug Discovery & Development Summit

pharmaphorum

Bringing together 100+ covalency experts, the 2nd Covalent Drug Discovery & Development Summit returns as the only dedicated forum to comprehensively cover discovery to translation and clinical development of covalent therapeutics.

52
article thumbnail

Helping Food and Beverage Companies Solve Compliance and Production Issues: Interview with Matt Brown, Wherefour

XTalks

This episode of the Xtalks Food Podcast features an interview with with Matt Brown, CEO of Wherefour, a cloud-based ERP (enterprise resource planning) platform that helps food and beverage companies, large and small, solve production and compliance issues. Matt discusses his background and what led him to lead Wherefour. He talks about why ERP platforms are crucial for early-stage food and beverage startups and advises when startups should transition to this technology.

52
article thumbnail

6th Inflammasome Therapeutics Summit

pharmaphorum

Seize this chance to network with top professionals committed to driving the future of inflammasome therapeutics at the 6th Inflammasome Therapeutics Summit, Boston MA, September 10th to 12th 2024.

52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Sentiments Surrounding At-Home Diagnostic Testing

Pharmaceutical Commerce

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s manager of biopharma, discusses findings of a new physician survey that the company conducted.

52
article thumbnail

UK life sciences can lead the way in cannabinoid R&D, says report

Drug Discovery World

The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report suggests the UK can build on the success of GW Pharmaceuticals, whose multiple sclerosis treatment product nabiximols was the first natural cannabis plant derivative to gain market approval in any country.

article thumbnail

Roche’s oral GLP-1 receptor agonist shows promising early weight loss results in phase 1

BioPharma Reporter

Rocheâs recent $2.7 billion acquisition of Carmot Therapeutics is paying off, with positive results for new oral GLP-1 receptor agonist.

59
article thumbnail

CatalYm raises $150m for cancer therapy visugromab

Drug Discovery World

CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III also participated in the round.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.